NCT01178294已完成2 期
Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
Baxalta now part of Shire24 个研究点 分布在 4 个国家目标入组 29 人开始时间: 2010年11月10日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 29
- 试验地点
- 24
- 主要终点
- Percentage of Serious Bleeding Episodes Responsive to OBI-1
研究概览
简要总结
This study is to test whether the study drug (OBI-1) is safe and effective for the treatment of serious bleeding episodes in people with acquired hemophilia A.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent from subject, trusted person or person who is legally authorized to sign on behalf of the participant (Legal Representative in U.S.), depending on local regulations
- •Participants with acquired hemophilia with autoimmune inhibitory antibodies to human factor VIII with a clinical diagnosis established by the following criteria: a) Prolonged activated partial thromboplastin time (aPTT), b) Prothrombin time (PT) ≤ upper limit of normal (ULN) + 2 seconds and platelet count within normal range, c) Abnormal aPTT mixing study (patient-normal control 1:1) consistent with a factor VIII inhibitors reduced factor VIII activity level (below 10%)
- •Has a serious bleeding episode, as documented by the investigator
- •Be willing and able to follow all instructions and attend all study visits
- •Participants taking anti-thrombotics (such as clopidogrel, heparin or heparin analogue) may be included provided three half-lives of the agent have elapsed since the last dose of the agent
- •Life expectancy, prior to onset of the hemorrhagic episode, of at least 90 days
- •Participants of reproductive age must use acceptable methods of contraception and if female, undergo pregnancy testing as part of the screening process
排除标准
- •Hemodynamically unstable after blood transfusion, fluid resuscitation and pharmacologic or volume replacement pressor therapy. This hemodynamic instability is characterized by symptomatic hypotension resulting in vital organ dysfunction, such as cardiac ischemia, oliguria (urine volume <0.5 mL/kg in the previous six hours), central nervous system hypoperfusion manifested by mental status change such as confusion (unless head injury or intracranial hemorrhage is present), pulmonary compromise, and/or acidosis (manifested by pH and lactate levels)
- •Has an established reason for bleeding that is not correctable
- •Bleeding episode assessed likely to resolve on its own if left untreated
- •Anti-OBI-1 inhibitor that exceeds 20 Bethesda Units (BU) (prospectively or retrospectively)
- •Subsequent bleeding episode at the site of the initial qualifying bleeding episode within two weeks following the final OBI-1 dose for the initial qualifying bleeding episode, or subsequent bleeding episode at a different site than the initial qualifying bleeding episode within 1 week following the final OBI-1 dose for the initial qualifying bleeding episode will not be considered "new" qualifying bleeding episodes
- •Prior history of bleeding disorder other than acquired hemophilia.
- •Known major sensitivity to therapeutic products of pig or hamster origin; examples include therapeutics of porcine origin (e.g. previously marketed porcine factor VIII, Hyate-C®) and recombinant therapeutics prepared from hamster cells (e.g. Humira®, Advate® and Enbrel®)
- •Use of hemophilia medication: rFVIIa within 3 hours prior to OBI-1 administration or aPCC treatment within 6 hours prior to OBI-1 administration
- •Participation in any other clinical study within 30 days of the first OBI-1 treatment
- •Anticipated need for treatment or device during the study that may interfere with the evaluation of the safety or efficacy of OBI-1, or whose safety or efficacy may be affected by OBI-1
- •Is currently pregnant, breastfeeding, or planning to become pregnant or father a child during the study
- •Abnormal baseline findings, any other medical condition(s) or laboratory findings that, in the opinion of the investigator, might jeopardize the subject's safety or decrease the chance of obtaining satisfactory data needed to achieve the objectives of the study
- •Inability or unwillingness to comply with the study design, protocol requirements, or the follow-up procedures
- •Participant of majority age under legal protection
结局指标
主要结局
Percentage of Serious Bleeding Episodes Responsive to OBI-1
时间窗: 24 hours after initiation of treatment
The initial serious ("qualifying") bleeding episode for each subject was analyzed for the primary efficacy outcome measure. A 'positive response' is defined as 'effective' (bleeding stopped with clinical control and FVIII levels of 50% or higher ) or 'partially effective' (bleeding reduced with clinical stabilization and FVIII levels of 20% or higher) control of bleeding, as determined by the investigator using a 4-point rating scale (effective - partially effective - poorly effective - not effective). 'Poorly effective' is defined as 'bleeding slightly reduced or unchanged and FVIII levels of less than 50%'. 'Not effective' is defined as 'bleeding worsening and FVIII levels of less than 50%'.
次要结局
- Percentage of Serious Bleeding Episodes Responsive to OBI-1 Therapy at Designated Assessment Time Points After the Initiation of Therapy, as Assessed by the Investigator(16 hours)
- Frequency of Infusions of OBI-1 Required to Successfully Control Qualifying Bleeding Episodes(Time of successful control of qualifying bleeding episode (varied from participant to participant))
- Pharmacokinetics (PK) Analysis- Plasma Clearance(Pre-infusion 15-20 minutes, Post-infusion 1, 3, 6, 12, 18, 24 hours)
- Correlation Between the Pre-infusion Anti-OBI-1 Antibody Titers, the Total Dose of OBI-1, the Outcome at 24 Hours and the Eventual Control of the Bleeding Episode(Through 90 days ± 7 days following final OBI-1 dose)
- Number of Participants Who Developed de Novo Anti-OBI-1 Antibody Titers(Through 90 days ± 7 days following final OBI-1 dose)
- Number of Participants Who Developed an Anti-host Cell Protein Baby Hamster Kidney (BHK) Antibody Titer(Through 90 days ± 7 days following final OBI-1 dose)
- Total Dose of OBI-1 Required to Successfully Control 'Qualifying' Bleeding Episodes(Time of successful control of qualifying bleeding episode (varied from participant to participant))
- PK Analysis- Area Under the Concentration-time Curve (AUC) From Time 0 to the Last Measurable Concentration(Pre-infusion 15-20 minutes, Post-infusion 1, 3, 6, 12, 18, 24 hours)
- Total Number of Infusions of OBI-1 Required to Successfully Control 'Qualifying' Bleeding Episodes(Time of successful control of qualifying bleeding episode (varied from participant to participant))
- Overall Percentage of Serious Bleeding Episodes Successfully Controlled With OBI-1 Therapy, as Assessed by the Investigator(At the time of final treatment dosing (varied from participant to participant depending on bleeding episodes))
- Correlation Between Positive Response to OBI-1 Therapy at 8 Hours and Eventual Control of Serious Bleeding Episodes at 24 Hours(24 hours)
- Correlation Between Response to OBI-1 Therapy at 16 Hours and Eventual Control of Serious Bleeding Episodes at 24 Hours(24 hours)
- Correlation Between Response to OBI-1 Therapy at Specified Time Points and Eventual Control of Serious Bleeding Episodes at 24 Hours(24 hours)
- PK Analysis- Volume of Distribution (Vd) at Steady State(Pre-infusion 15-20 minutes, Post-infusion 1, 3, 6, 12, 18, 24 hours)
- PK Analysis- Terminal Half-life(Pre-infusion 15-20 minutes, Post-infusion 1, 3, 6, 12, 18, 24 hours)
研究者
研究点 (24)
Loading locations...
相似试验
终止
3 期
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia AHemophilia ANCT01434511Baxalta now part of Shire1
已完成
2 期
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia ACTRI/2012/03/002487Baxter Innovations GmbH28
进行中（未招募）
1 期
Study of a new factor VIII replacement for patients with congenitalhemophilia ACongenital Hemophilia A with factor VIII inhibitorsMedDRA version: 14.1Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850EUCTR2011-001899-18-GBBaxter Innovations GmbH28
进行中（未招募）
不适用
Study of a new factor VIII replacement for patients with acquired hemophilia AAcquired Haemophilia AMedDRA version: 16.0Level: LLTClassification code 10053761Term: Acquired hemophilia with anti FVIII, XI, or XIIISystem Organ Class: 100000004851EUCTR2011-000181-34-SEBaxter Innovations GmbH28
进行中（未招募）
不适用
Study of a new factor VIII replacement for patients with acquired hemophilia AAcquired Haemophilia AMedDRA version: 16.0Level: LLTClassification code 10053761Term: Acquired hemophilia with anti FVIII, XI, or XIIISystem Organ Class: 100000004851EUCTR2011-000181-34-DEBaxter Innovations GmbH28